{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:06:33Z","timestamp":1793995593901,"version":"4.8.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4140,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"French Minister of Health"},{"name":"Assistance Publique-H\u00f4pitaux de Paris"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Tumor necrosis factor-\u03b1 (TNF-\u03b1) may contribute to the progression of acute alcoholic hepatitis (AAH). The aim of this study was to evaluate the efficacy of an association of infliximab and prednisolone at reducing the 2-month mortality rate among patients with severe AAH. Patients with severe AAH (Maddrey score \u226532) were randomly assigned to group A receiving intravenous infusions of infliximab (10 mg\/kg) in weeks 0, 2, and 4; or group B receiving a placebo at the same times. All patients received prednisolone (40 mg\/day) for 28 days. Blood neutrophil functional capacities were monitored over 28 days. After randomization of 36 patients, seven patients from group A and three from group B died within 2 months. The probability of being dead at 2 months was higher (not significant [NS]) in group A (39% \u00b1 11%) than in group B (18% \u00b1 9%). The study was stopped by the follow-up committee and the sponsor (Assistance Publique-H\u00f4pitaux de Paris). The frequency of severe infections within 2 months was higher in group A than in group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .002). This difference was potentially related to a significantly lower\n                      <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                      stimulation capacity of neutrophils. There were no differences between the two groups in terms of Maddrey scores at any time point. In conclusion, three infusions of 10 mg\/kg of infliximab in association with prednisolone may be harmful in patients with severe AAH because of the high prevalence of severe infections. (Hepatology 2004;39:1390-1397.)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.20206","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T19:02:10Z","timestamp":1083006130000},"page":"1390-1397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":378,"title":["A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis"],"prefix":"10.1097","volume":"39","author":[{"given":"Sylvie","family":"Naveau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chollet-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Dharancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Jouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Astrid","family":"Piquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Davion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Oberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bro\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Emilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20241201","first-page":"521","article-title":"Le traitement de lhepatite alcoolique. Une revue des essais randomises.","volume":"12","author":"Perrot","year":"1988","journal-title":"Gastroenterol Clin Biol"},{"key":"R2-26-20241201","first-page":"137","article-title":"Mechanisms of the inflammatory reaction implicated in acute experimental alcoholic hepatitis.","volume":"25","author":"Naveau","year":"2001","journal-title":"Gastroenterol Clin Biol"},{"key":"R3-26-20241201","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM200011163432007","article-title":"Cytokines in alcoholic and nonalcoholic steatohepatitis.","volume":"343","author":"Tilg","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-26-20241201","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/hep.510260621","article-title":"Antibodies to tumor necrosis factor alpha attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat.","volume":"26","author":"Iimuro","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R5-26-20241201","first-page":"548","article-title":"Alcoholic hepatitis-glucocorticoids or not?","volume":"547-","author":"Christensen","year":"2002","journal-title":"J Hepatol"},{"key":"R6-26-20241201","first-page":"223","article-title":"Place de la corticotherapie dans le traitement des hepatites alcooliques aigues. Resultats dune metaanalyse.","volume":"15","author":"Daures","year":"1991","journal-title":"Gastroenterol Clin Biol"},{"key":"R7-26-20241201","first-page":"208","article-title":"Treatment of alcoholic hepatitis.","volume":"2","author":"Reynolds","year":"1989","journal-title":"Gastroenterol Int"},{"key":"R8-26-20241201","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-113-4-299","article-title":"Do corticosteroids reduce mortality from alcoholic hepatitis?","volume":"113","author":"Imperial","year":"1990","journal-title":"Ann Intern Med"},{"key":"R9-26-20241201","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0168-8278(01)00289-6","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.","volume":"36","author":"Mathurin","year":"2002","journal-title":"J Hepatol"},{"key":"R10-26-20241201","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1572-0241.1998.00587.x","article-title":"Alcoholic liver disease: proposed recommendations for the American college of gastroenterology.","volume":"93","author":"Mc Cullough","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R11-26-20241201","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0168-8278(03)00045-X","article-title":"Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?","volume":"38","author":"Poynard","year":"2003","journal-title":"J Hepatol"},{"key":"R12-26-20241201","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions cytokine release in severe alcoholic hepatitis: effects of corticoids.","volume":"32","author":"Taieb","year":"2000","journal-title":"J Hepatol"},{"key":"R13-26-20241201","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"R14-26-20241201","first-page":"707","article-title":"Review by an international group, alcoholic liver disease morphological manifestations.","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"R15-26-20241201","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn disease.","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"R16-26-20241201","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00063030-199810050-00006","article-title":"Infliximab A review of its use in Crohns disease and rheumatoid arthritis.","volume":"10","author":"Onrust","year":"1998","journal-title":"Biodrugs"},{"key":"R17-26-20241201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 3","key":"R18-26-20241201","first-page":"1252","article-title":"Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohns disease patients. Abstract.","volume":"59","author":"Wagner","year":"1998","journal-title":"Digestion"},{"key":"R19-26-20241201","first-page":"311","article-title":"Spontaneous bacterial peritonitis: pathogenesis, diagnosis and management.","volume":"3","author":"Guarner","year":"1995","journal-title":"Gastroenterologist"},{"key":"R20-26-20241201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2307\/2530822","article-title":"Group sequential clinical trials with triangular continuation region.","volume":"39","author":"Whithead","year":"1983","journal-title":"Biometrics"},{"key":"R21-26-20241201","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.0006-341X.1999.00874.x","article-title":"A unifying family of groups sequential test designs.","volume":"55","author":"Kittelson","year":"1999","journal-title":"Biometrics"},{"key":"R22-26-20241201","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study.","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"R23-26-20241201","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0168-8278(02)00442-7","article-title":"Anti tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.","volume":"38","author":"Tilg","year":"2003","journal-title":"J Hepatol"},{"key":"R24-26-20241201","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.1840130211","article-title":"Circulating tumor necrosis factor, interleukin-1 and interleukine-6 concentrations in chronic alcoholic patients.","volume":"13","author":"Khorus","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R25-26-20241201","first-page":"247","article-title":"Circulating and mucosal concentrations of tumor necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.","volume":"40","author":"Nielsen","year":"1993","journal-title":"Dan Med Bull"},{"key":"R26-26-20241201","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"R27-26-20241201","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0264-410X(03)00196-8","article-title":"Anti-cytokine therapeutics and infections.","volume":"21","author":"Dinarello","year":"2003","journal-title":"Vaccine"},{"key":"R28-26-20241201","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R29-26-20241201","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor -neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R30-26-20241201","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohns disease: the Mayo Clinic experience inn 500 patients.","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"R31-26-20241201","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/15419069809005606","article-title":"Neutralization of TNF bye the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells.","volume":"5","author":"Nakada","year":"1998","journal-title":"Cell Adhes Commun"},{"key":"R32-26-20241201","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohns disease by using a caspase-dependent pathway.","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"R33-26-20241201","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages.","volume":"164","author":"Eissner","year":"2000","journal-title":"J Immunol"},{"key":"R34-26-20241201","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.4049\/jimmunol.171.8.4392","article-title":"TNF- induces phosphorylation of p47phox is a common event of priming of human neutrophils by TNF- and granulocyte-macrophage colony-stimulating factor.","volume":"171","author":"Dewas","year":"2003","journal-title":"J Immunol"},{"key":"R35-26-20241201","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-8278(05)80267-3","article-title":"Bacterial infections in patients with cirrhosis.","volume":"18","author":"Runyon","year":"1993","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20206","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200405000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T06:30:49Z","timestamp":1733034649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200405000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20206","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}